202
Alzheimer’s Disease
Nevertheless, treatment with statins and
other cholesterol-reducing drugs may have
a signifcant clinical beneft in the preven-
tion oF AD.
6
Summary
We have seen a dramatic increase in our
knowledge oF the underlying molecular
mechanisms oF AD pathology during the
last ten years. Understanding the eFFects
oF causative mutations in
APP
and the
presenilins and the genetic risk Factor,
APOE4
has led to the conclusion that
changes in A
β
metabolism and deposition
are central to the disease process. These
studies suggest that similar mechanisms
underlie both ±AD and sporadic AD.
Transgenic models oF AD now provide
a new hope For the rapid development in
rational treatments For AD.
See also
Brain Development; Medic-
inal Chemistry.
Bibliography
Books and Reviews
DuFF, K.
(2001)
Transgenic
mouse
models
oF
Alzheimer’s
disease:
phenotype
and
mechanisms oF pathogenesis,
Biochem. Soc.
Symp.
67
, 195–202.
Golde, T.E. (2003) Alzheimer disease therapy:
Can the amyloid cascade be halted?
J. Clin.
Invest.
11
, 11–18.
Hardy, J.,
Selkoe, D.J.
(2002)
The
amyloid
hypothesis oF Alzheimer’s disease: progress
and problems on the road to therapeutics,
Science
297
, 353–356.
Myers, A., Goate, A.M. (2001) The genetics oF
late-onset Alzheimer’s disease,
Curr. Opin.
Neurol.
14
, 433–440.
Richardson, J.A.,
Burns, D.K.
(2002)
Mouse
models oF Alzheimer’s disease: a quest For
plaques and tangles,
ILAR J.
43
, 89–99.
Selkoe, D.J., Podlisny, M.B. (2002) Deciphering
the genetic basis oF Alzheimer’s disease,
Annu.
Rev. Genomics Hum. Genet.
3
, 67–99.
Tandon, A., ±raser, P. (2002) The presenilins,
Genome Biol.
3
, 3014.1–3014.9; reviews.
Vassar, R. (2002)
β
-Secretase (BACE) as a drug
target
For alzheimer’s disease,
Adv.
Drug
Delivery Rev.
54
, 1589–1602.
Primary Literature
Alzheimer, A.
(1907)
¨
Uber
eine
eigenartige
Erkrankung
der
Hirnrinde,
Allg.
Zeitsch.
Psychiatrie
Psychisch-gerichtliche
Med.
64
,
146–148.
B
ierna
t
,J
.
,Gus
tke
,N
.
,Drewes
,G
.
,Mande
lkow
,
E.M.,
Mandelkow, E.
Phosphorylation
oF
Ser262 strongly reduces binding oF tau to
microtubules: distinction between PH±-like
immunoreactivity and microtubule binding,
Neuron
11
, 153–163.
Blacker, D., Bertram, L., Saunders, A.J., Mos-
carillo, T.J., Albert, M.S., Wiener, H., Perry,
R.T., Collins, J.S., Harrell, L.E., Go, R.C., Ma-
honey, A., Beaty, T., ±allin, M.D., Avramopou-
los, D.,
Chase, G.A.,
±olstein, M.±.,
McIn-
nis, M.G., Bassett, S.S., Doheny, K.J., Pugh,
E.W., Tanzi, R.E. (2003) Results oF a high-
resolution genome screen oF 437 Alzheimer’s
disease Families,
Hum. Mol. Genet.
12
, 23–32.
Borchelt,
D.R.,
Ratovitski,
T.,
van
Lare, J.,
Lee,
M.K.,
Gonzales, V.,
Jenkins, N.A.,
Copeland,
N.G.,
Price, D.L.,
Sisodia, S.S.
(1997) Accelerated amyloid deposition in the
brains oF transgenic mice coexpressing mutant
presenilin 1 and amyloid precursor proteins,
Neuron
19
, 939–945.
Borchelt, D.R.,
Thinakaran, G.,
Eckman, C.B.,
Lee, M.K., Davenport, ±., Ratovitsky, T., Prada,
C.M., Kim, G., Seekins, S., Yager, D., Slunt,
H.H.,
Wang, R.,
Seeger, M.,
Levey, A.I.,
Gandy, S.E., Copeland, N.G., Jenkins, N.A.,
Price, D.L., Younkin, S.G., Sisodia, S.S. (1996)
±amilial Alzheimer’s disease-linked presenilin
1 variants elevate A
β
1-42/1-40 ratio
in vitro
and
in vivo
,
Neuron
17
, 1005–1013.
Braak, H., Braak, E. (1991) Neuropathological
stageing oF Alzheimer-related changes,
Acta
Neuropathol. (Berl)
82
, 239–259.
previous page 202 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online next page 204 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online Home Toggle text on/off